Covered recipient · General Payments record
DAVID ADDIS HORVATH
Allopathic & Osteopathic Physicians Surgery Plastic and Reconstructive Surgery
General Payments · PY2018–2024
$1,530.29
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $298.07 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| QOL Medical, LLC | $90.84 | 5 |
| Novo Nordisk AS | $76.98 | 4 |
| Janssen Biotech, Inc. | $44.58 | 3 |
| GlaxoSmithKline, LLC. | $30.85 | 1 |
| Dermavant Sciences, Inc. | $21.84 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.40 | 1 |
| EISAI INC. | $15.58 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Dermavant Sciences, Inc. | $21.84 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127880386 | CMS |
| Eisai Inc. | $15.58 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110740099 | CMS |
| GlaxoSmithKline, LLC. | $30.85 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116556537 | CMS |
| Janssen Biotech, Inc. | $16.99 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078572859 | CMS |
| Janssen Biotech, Inc. | $13.28 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078572902 | CMS |
| Janssen Biotech, Inc. | $14.31 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078572898 | CMS |
| Novo Nordisk Inc | $20.19 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096710762 | CMS |
| Novo Nordisk Inc | $14.76 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096718222 | CMS |
| Novo Nordisk Inc | $14.63 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096958762 | CMS |
| Novo Nordisk Inc | $27.40 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097332003 | CMS |
| QOL Medical, LLC | $20.49 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147729090 | CMS |
| QOL Medical, LLC | $17.82 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147729092 | CMS |
| QOL Medical, LLC | $15.78 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147729094 | CMS |
| QOL Medical, LLC | $22.20 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147729096 | CMS |
| QOL Medical, LLC | $14.55 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147729098 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.40 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137579632 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.